N-[3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-2-sulfanylbenzamide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-2-sulfanylbenzamide
• 化学式: C₂₂H₁₇N₅OS
• 分子量: 399.476
• InChiKey: SIEOYRNUJRGYMT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  29
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  80.8
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  3-乙酰基吡啶 在 palladium on activated charcoal 氢气 作用下， 以 异丙醇 为溶剂， 生成 N-[3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-2-sulfanylbenzamide
  参考文献：
  名称：

  Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives

  摘要：

  Due to its relatively clear etiology, Chronic myelogenous leukemia (CML) represents an ideal disease target for a therapy using a selective inhibitor of the Bcr-Abl tyrosine protein kinase. Extensive optimization of the class of phenylamino-pyrimidines yielded highly potent and selective Bcr-Abl kinase inhibitors. Compound 1 shows high potency (IC50 = 38 nM) and selectivity for the Abl tyrosine protein kinase at the in vitro level. (C) 1997, Elsevier Science Ltd.

  DOI：

  10.1016/s0960-894x(96)00601-4

文献信息

• Potent and selective inhibitors of the Abl-kinase: phenylamino-pyrimidine (PAP) derivatives
  作者：Jürg Zimmermann、Elisabeth Buchdunger、Helmut Mett、Thomas Meyer、Nicholas B. Lydon

  DOI：10.1016/s0960-894x(96)00601-4

  日期：1997.1

  Due to its relatively clear etiology, Chronic myelogenous leukemia (CML) represents an ideal disease target for a therapy using a selective inhibitor of the Bcr-Abl tyrosine protein kinase. Extensive optimization of the class of phenylamino-pyrimidines yielded highly potent and selective Bcr-Abl kinase inhibitors. Compound 1 shows high potency (IC50 = 38 nM) and selectivity for the Abl tyrosine protein kinase at the in vitro level. (C) 1997, Elsevier Science Ltd.